Work

Potential depressive central nervous system effects of brimonidine topical gel

Year: 2020
Type: article
Abstract: Brimonidine 0.33% topical gel is a Food and Drug Administration–approved treatment for rosacea that acts as an α2a-adrenergic agonist on cutaneous vessels, resulting in vasoconstriction.1 Within the central nervous system, stimulation of these receptors has the opposite effect, inhibiting adrenergic neurotransmission and resulting in central nervous system depression.2 Although its clinical use is to act at the peripheral α2a-adrenergic receptors, its highly lipophilic nature may allow it to act at inner central nervous system α2a-receptors, resulting in depressive effects.
Language: English
Subfield: Dermatology
Field: Medicine
Open Access status: gold
Estimated APC paid: $600
OpenAlex ID: W3045767553
FWCI:
Cites: 8
Cited by:
Related to: 10